Intercept’s OCA Facing Extended Approval Wait In NASH As Known Risks Swamp Uncertain Benefits

Obeticholic acid clinical outcomes data from Phase III trial are needed before approval, US FDA advisory committee says, but Intercept suggests future of ongoing study is in doubt if accelerated approval in nonalcoholic steatohepatitis is not forthcoming now.